Prof-003

Prof-003 is a preclinical drug candidate being developed by ProFem, an Austrian biotechnology company specializing in women's health. It is intended for the treatment of atrophic vaginitis (also known as vaginal atrophy), a condition characterized by the thinning, drying, and inflammation of the vaginal walls, typically due to a decline in estrogen levels during menopause. Currently in the preclinical/Proof of Concept (PoC) stage, the specific modality and molecular mechanism of action for Prof-003 have not been publicly disclosed by the developer. ProFem's broader portfolio focuses on novel treatments for gynecological and urogenital conditions, often targeting biofilm-associated disease mechanisms.